Pacific Hospital Supply Co., Ltd. AI Stock Analysis
Pacific Hospital Supply Co., Ltd. (4126) AI Stock Analysis
Pacific Hospital Supply Co., Ltd.
(TPEx:4126)
The score is primarily supported by very low leverage, strong cash generation, healthy absolute profitability, and attractive valuation. These strengths are offset by weakening 2025 financial performance and bearish technical momentum, despite deeply oversold indicators.
Pacific Hospital Supply Co., Ltd. (4126) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 5.40B
- Dividend Yield
- 6.00%
- Average Volume (3M)
- 33.73K
- Price to Earnings (P/E)
- 12.5
- Beta (1Y)
- 0.11
- Revenue Growth
- 1.32%
- EPS Growth
- 7.25%
- Country
- TW
- Employees
- 812
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Pacific Hospital Supply Co., Ltd. Business Overview & Revenue Model
Company Description
Pacific Hospital Supply Co., Ltd., together with its subsidiaries, manufactures, processes, and sells medical disposable products and equipment in Taiwan. The company’s disposable medical devices include tubings, bags, bottles, closed wound drainage...
Pacific Hospital Supply Co., Ltd. Financial Statement Overview
Summary
Strong balance sheet and cash generation support the score: debt-to-equity was 0.15, equity reached 2.97 billion, and free cash flow grew 157.4%. The score is moderated by declining 2025 revenue, margins, net income, and return on equity.
Income Statement
72PositiveBalance Sheet
90Very PositiveCash Flow
87Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.42B | 2.41B | 2.35B | 2.32B | 2.18B | 2.02B |
| Gross Profit | 722.62M | 724.71M | 746.84M | 739.75M | 587.97M | 523.42M |
| EBITDA | 663.67M | 612.06M | 699.23M | 673.80M | 568.57M | 602.81M |
| Net Income | 434.16M | 382.87M | 447.85M | 420.79M | 331.40M | 386.42M |
Balance Sheet | ||||||
| Total Assets | 4.19B | 3.92B | 3.88B | 3.77B | 3.65B | 3.80B |
| Cash, Cash Equivalents and Short-Term Investments | 1.39B | 1.16B | 1.10B | 990.62M | 688.29M | 815.27M |
| Total Debt | 430.79M | 432.89M | 432.30M | 437.43M | 439.53M | 675.73M |
| Total Liabilities | 1.33B | 951.83M | 939.57M | 934.34M | 929.03M | 1.09B |
| Stockholders Equity | 2.86B | 2.97B | 2.94B | 2.83B | 2.72B | 2.71B |
Cash Flow | ||||||
| Free Cash Flow | 480.04M | 467.89M | 456.57M | 620.72M | 394.15M | 285.14M |
| Operating Cash Flow | 568.21M | 542.15M | 505.24M | 653.63M | 431.66M | 319.11M |
| Investing Cash Flow | -221.18M | -75.22M | -150.78M | -273.74M | -26.31M | 382.65M |
| Financing Cash Flow | -375.18M | -374.87M | -358.76M | -312.72M | -564.34M | -482.49M |
Pacific Hospital Supply Co., Ltd. Peers Comparison
Overall Rating
TW:412672Outperform
TW:416670Outperform
TW:474664Neutral
TW:178863Neutral
TW:416455Neutral
TW:411948Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | TWD 5.39B | 12.54 | ― | 6.00% | 1.32% | 7.25% | |
| 70Outperform | TWD 5.47B | 22.78 | ― | ― | ― | ― | |
| 64Neutral | TWD 5.43B | 11.42 | ― | 6.61% | -2.71% | ― | |
| 63Neutral | TWD 5.57B | 14.19 | ― | 5.56% | 7.58% | 13.04% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | TWD 4.79B | 21.84 | ― | 4.45% | 11.83% | 27.86% | |
| 48Neutral | TWD 5.85B | 95.69 | ― | 1.55% | -18.83% | -87.54% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4126 | Pacific Hospital Supply Co., Ltd. | 75.00 | -8.51 | -10.19% | |
| TW:1788 | Hi-Clearance Inc. | 126.00 | -4.42 | -3.39% | |
| TW:4119 | SCI Pharmtech Corp. | 48.50 | -0.42 | -0.85% | |
| TW:4164 | CHC Healthcare Group | 24.90 | -15.58 | -38.48% | |
| TW:4166 | Orient Pharma Co., Ltd. | 22.55 | -1.95 | -7.96% | |
| TW:4746 | Formosa Laboratories, Inc. | 45.40 | -15.89 | -25.92% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
